684 related articles for article (PubMed ID: 28823713)
1. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.
Vietti Violi N; Gnerre J; Law A; Hectors S; Bane O; Doucette J; Abboud G; Kim E; Schwartz M; Fiel MI; Taouli B
Eur Radiol; 2022 Sep; 32(9):6493-6503. PubMed ID: 35380226
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
4. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
Vouche M; Kulik L; Atassi R; Memon K; Hickey R; Ganger D; Miller FH; Yaghmai V; Abecassis M; Baker T; Mulcahy M; Nayar R; Lewandowski RJ; Salem R
Hepatology; 2013 Nov; 58(5):1655-66. PubMed ID: 23703789
[TBL] [Abstract][Full Text] [Related]
5. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.
Chapiro J; Wood LD; Lin M; Duran R; Cornish T; Lesage D; Charu V; Schernthaner R; Wang Z; Tacher V; Savic LJ; Kamel IR; Geschwind JF
Radiology; 2014 Dec; 273(3):746-58. PubMed ID: 25028783
[TBL] [Abstract][Full Text] [Related]
6. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
8. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
[TBL] [Abstract][Full Text] [Related]
9. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
[TBL] [Abstract][Full Text] [Related]
10. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ
Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
[TBL] [Abstract][Full Text] [Related]
11. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.
Kim S; Mannelli L; Hajdu CH; Babb JS; Clark TW; Hecht EM; Taouli B
J Magn Reson Imaging; 2010 Feb; 31(2):348-55. PubMed ID: 20099348
[TBL] [Abstract][Full Text] [Related]
13. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
Donati OF; Do RK; Hötker AM; Katz SS; Zheng J; Moskowitz CS; Beattie C; Brown KT
Eur Radiol; 2015 Sep; 25(9):2779-88. PubMed ID: 25850892
[TBL] [Abstract][Full Text] [Related]
14. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
Ahmed AF; Samreen N; Grajo JR; Zendejas I; Sistrom CL; Collinsworth A; Esnakula A; Shah JL; Cabrera R; Geller BS; Toskich BB
Abdom Radiol (NY); 2018 Jul; 43(7):1825-1836. PubMed ID: 29052747
[TBL] [Abstract][Full Text] [Related]
15. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
16. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
18. Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy.
Gordic S; Ayache JB; Kennedy P; Besa C; Wagner M; Bane O; Ehman RL; Kim E; Taouli B
Abdom Radiol (NY); 2017 Jun; 42(6):1685-1694. PubMed ID: 28154910
[TBL] [Abstract][Full Text] [Related]
19. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
